CP-023 Use of intravitreal antiangiogenic drug in a large study in the treatment of retinopathy of prematurity
| Autor: | S Cañizares Paz, FD Fernández-Ginés, E Molina-Cuadrado, TB Rodríguez-Cuadros |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
congenital
hereditary and neonatal diseases and abnormalities medicine.medical_specialty genetic structures business.industry Gestational age Retinal detachment Retrospective cohort study Retinopathy of prematurity Retinal medicine.disease eye diseases Surgery Discontinuation chemistry.chemical_compound Endophthalmitis chemistry Ophthalmology medicine sense organs business Retinopathy |
| Zdroj: | Clinical pharmacy. |
| DOI: | 10.1136/ejhpharm-2017-000640.22 |
| Popis: | Background Retinopathy of prematurity (ROP) is a proliferative disease of the retinal vasculature that can cause severe visual loss in premature newborns. Intravitreal bevacizumab has shown promise as a treatment for ROP. Purpose To evaluate the efficacy and safety of intravitreal bevacizumab in preterm infants with retinopathy diagnosed with grades 1–3+. Material and methods This was a retrospective study of 24 months’ duration involving patients less than 30 weeks’ gestational age diagnosed with ROP to grade 3+ and weighing Results 9 patients (6 men and 3 women) were included, with a mean gestational age of 25 weeks (23, 29). Previous diagnoses were: 2 patients with aggressive ROP in BE, 2 patients with grade 3 ROP in zone 2+ in BE, 1 patient with grade 2 ROP in zone 2+ in BE, 2 patients with grade 1 ROP in zone 2 in BE and zone 3 ROP in 1 patient and 1 patient with ROP in zone 3 in the right eye and temporal zone II ROP I festooned in the left eye. The primary efficacy criterion (CV in BE) was achieved in 7/9 cases, with an average time to BE and CV of 4 months (1, 6). Furthermore, in 5 patients, an early response was achieved in BE at week 4. During the study period, no endophthalmitis, retinal detachment or systemic side effects resulting in discontinuation of treatment occurred. Conclusion This study shows that intravitreal bevacizumab was used effectively and safely in the treatment of variable degrees of ROP, achieving 85% CV. References and/or acknowledgements To my pharmacist colleagues. No conflict of interest |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|